美国 · SEC FORM 4
Generation Bio Co.
GBIO · — · CIK 0001733294 · Healthcare
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-01-13 · Quinn Anthony G..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-01-13 | Quinn Anthony G. | 买入 (P) | Common Stock | 85,000 | USD 0.97 | USD 82,450 | SEC 申报 ↗ |
| 2025-01-10 | Quinn Anthony G. | 买入 (P) | Common Stock | 125,791 | USD 0.96 | USD 120,759 | SEC 申报 ↗ |
| 2023-12-08 | Appelhans Dannielle | 买入 (P) | Common Stock | 8,000 | USD 1.79 | USD 14,339 | SEC 申报 ↗ |
| 2023-12-04 | Appelhans Dannielle | 买入 (P) | Common Stock | 12,000 | USD 1.50 | USD 18,000 | SEC 申报 ↗ |
| 2023-12-04 | Rowland Charles A Jr | 买入 (P) | Common Stock | 150,000 | USD 1.50 | USD 225,000 | SEC 申报 ↗ |
| 2023-12-01 | Rowland Charles A Jr | 买入 (P) | Common Stock | 192,960 | USD 1.31 | USD 252,778 | SEC 申报 ↗ |
| 2023-12-01 | Quinn Anthony G. | 买入 (P) | Common Stock | 88,495 | USD 1.41 | USD 124,778 | SEC 申报 ↗ |
| 2023-12-01 | Nicholson Donald William | 买入 (P) | Common Stock | 100,000 | USD 1.44 | USD 144,000 | SEC 申报 ↗ |
| 2022-09-19 | Rowland Charles A Jr | 买入 (P) | Common Stock | 15,750 | USD 5.26 | USD 82,845 | SEC 申报 ↗ |
| 2022-09-16 | Rowland Charles A Jr | 买入 (P) | Common Stock | 33,481 | USD 5.48 | USD 183,476 | SEC 申报 ↗ |
| 2022-09-15 | Rowland Charles A Jr | 买入 (P) | Common Stock | 17,147 | USD 5.41 | USD 92,765 | SEC 申报 ↗ |
| 2022-09-14 | Rowland Charles A Jr | 买入 (P) | Common Stock | 5,600 | USD 5.30 | USD 29,680 | SEC 申报 ↗ |
| 2022-09-13 | Rowland Charles A Jr | 买入 (P) | Common Stock | 18,784 | USD 5.20 | USD 97,677 | SEC 申报 ↗ |
| 2022-03-10 | Nicholson Donald William | 买入 (P) | Common Stock | 8,126 | USD 4.71 | USD 38,273 | SEC 申报 ↗ |
| 2022-03-09 | Nicholson Donald William | 买入 (P) | Common Stock | 2,293 | USD 4.79 | USD 10,983 | SEC 申报 ↗ |
Form 4 申报证据
34 transaction lines in the latest 365-day window; 483 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Stehman-Breen Catherine | U (U) | Common Stock | 4,752 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Rowland Charles A Jr | U (U) | Common Stock | 53,475 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Rhodes Jason P | U (U) | Common Stock | 827,946 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (26 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-02-09 | Stehman-Breen Catherine | U (U) | Common Stock | 4,752 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Rowland Charles A Jr | U (U) | Common Stock | 53,475 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Rhodes Jason P | U (U) | Common Stock | 827,946 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Quinn Anthony G. | U (U) | Common Stock | 37,211 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Nicholson Donald William | U (U) | Common Stock | 21,357 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | MCDONOUGH GEOFF | U (U) | Common Stock | 188,638 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Howze Yalonda | U (U) | Common Stock | 3,759 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Cooper Ronald Harold Wilfred | U (U) | Common Stock | 950 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Conway Kevin John | U (U) | Common Stock | 2,072 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Christensen Gustav | U (U) | Common Stock | 13,142 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | Appelhans Dannielle | U (U) | Common Stock | 1,999 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-09 | ATLAS VENTURE ASSOCIATES X, L.P.; Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates X, LLC; Atlas Venture Fund X, L.P.; Atlas Venture Opportunity Fund I, L.P. | U (U) | Common Stock | 827,946 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-02 | MCDONOUGH GEOFF | 期权行权/转换 (M) | Common Stock | 1,582 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-02 | MCDONOUGH GEOFF | 代扣税 (F) | Common Stock | 550 | USD 5.64 | USD 3,102 | SEC 申报 ↗ |
| 2026-02-02 | Howze Yalonda | 期权行权/转换 (M) | Common Stock | 1,673 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-02 | Howze Yalonda | 代扣税 (F) | Common Stock | 495 | USD 5.64 | USD 2,792 | SEC 申报 ↗ |
| 2026-02-02 | Conway Kevin John | 期权行权/转换 (M) | Common Stock | 235 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-02 | Conway Kevin John | 代扣税 (F) | Common Stock | 72 | USD 5.64 | USD 406 | SEC 申报 ↗ |
| 2026-01-15 | MCDONOUGH GEOFF | 期权行权/转换 (M) | Common Stock | 395 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-15 | MCDONOUGH GEOFF | 代扣税 (F) | Common Stock | 137 | USD 5.64 | USD 773 | SEC 申报 ↗ |
| 2026-01-15 | Howze Yalonda | 期权行权/转换 (M) | Common Stock | 335 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-15 | Howze Yalonda | 代扣税 (F) | Common Stock | 99 | USD 5.64 | USD 558 | SEC 申报 ↗ |
| 2026-01-15 | Conway Kevin John | 期权行权/转换 (M) | Common Stock | 59 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-15 | Conway Kevin John | 代扣税 (F) | Common Stock | 17 | USD 5.64 | USD 96 | SEC 申报 ↗ |
| 2025-10-31 | MCDONOUGH GEOFF | 期权行权/转换 (M) | Common Stock | 659 | USD — | USD — | SEC 申报 ↗ |
| 2025-10-31 | MCDONOUGH GEOFF | 代扣税 (F) | Common Stock | 293 | USD 5.51 | USD 1,614 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | GBIO |
| CIK | 0001733294 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 483 transaction lines from 2020-06-16 to 2026-02-09 25 P purchase lines · 167 S sale lines · 291 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.